accūrō Solutions acquires Splashlight Solutions

“The acquisition reflects our investors’ commitment to the long-term growth and development of accūrō Solutions as the premiere service provider in the medical bill review industry,” said Chris Feeney, Executive Board Member of accūrō Solutions.

accūrō Solutions which manages medical bill review and payment processes for payers in the property and casualty industry, has acquired Splashlight Solutions, a national workers’ compensation bill review service provider based in West Des Moines, Iowa. The purchase price was not disclosed.

“The acquisition brings us additional proven resources to support our growth, improve efficiencies and continue to generate positive outcomes for our clients,” accūrō Solutions CEO Kenneth Hannigan, DBA said. “We built an amazing technology platform that automates many functions, yet its potential is only maximized when used by experienced professionals who have such a deep understanding of the P&C industry.”

All Splashlight employees have joined accūrō Solutions, with its CEO and Founder Lisa Gran now serving as Chief Revenue Officer. In addition, Mike Knutter, who led Splashlight’s operations, has become Assistant Vice President of Bill Review.

The deal came about when Gran was investigating technology options to enhance Splashlight’s bill review services. “We wanted something fresh, new, and flexible and were very impressed by accūrō Solutions’ ARC platform,” she said. As conversations continued, Gran and Dr. Hannigan realized it made sense to combine the two companies.

“The acquisition reflects our investors’ commitment to the long-term growth and development of accūrō Solutions as the premiere service provider in the medical bill review industry,” said Chris Feeney, Executive Board Member of accūrō Solutions.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.